EFFECT OF egc SUPERANTIGENS ON MALIGNANT BAND T CELLS. RATIONALE FOR COMBINATION WITH CURRENT ANTITUMOR THERAPIES

VERGARA RUBIO, MARICEF; REDOLFI, DANIELA; SARRATEA, MARIA B.; CECILIA C. VILA; IANNANTUONO LÓPEZ, LAURA; NOLI TRUANT, SOFIA ; MALUSARDI, CECILIA; CORDINI, GREGORIO; MALCHIODI, EMILIO L.; LOMPARDIA, SILVINA L; FERNÁNDEZ, MARISA MARIEL

San Luis

Congreso; LXXI Reunión Anual de la Sociedad Argentina de Inmunología; 2023

Sociedad Argentina de Inmunología

Lymphomas/leukemias are prevalent T and B-cell hematologic malignancies.Conventional treatment, encompassing radiotherapy and chemotherapy, not onlyyields limited tumor-specific outcomes but also incurs significant adverse effects.Thus, targeted therapies with less toxicity are essential to improve treatmentoutcomes. Immunotherapy´s rise in oncohematological care and monoclonalantibody integration into therapeutic strategies underscore the need for tumorexclusive antigens, as most antibodies currently target shared antigens in normaltissues. On the other hand, strategies that attempt to induce a host immuneresponse to the tumor require adequate immunogenicity of the neoplastic cells incontext of immunocompromisedpatients. In contrast to conventional antigens,superantigens (SAgs) are viral or bacterial proteins that interact with conventionaltargets such as variable region of the T-cell antigen receptor (TCR) and differentregions of the Major Histocompatibility Complex molecules type II (MHC-II). Theaim of this study was to investigate the effects of T SAgs on Hodgkin and nonHodgkin lymphomas and acute lymphocytic leukemia cell lines. Additionally, weaimed to assess the extent of these effects in combination with low doses ofVincristine (VCR), a vinca alkaloid primarily used as a chemotherapeutic agentwith well-described toxicity.We observed an increase in the expression of lateactivation markers (CD86) on the surface of malignant B cells, as measured byflow cytometry, after 48 hours of treatment with egc operon SAgs (SEG and SEI)at 10µg/mL.At 72 and 96 hours, we found a decrease in metabolic activity usingthe XTT assay for all B cell lines treated with 100µg/mL of SAgs (p